Quarterly ResultMay 7, 2026, 04:20 PM
Werewolf Therapeutics Q1 Net Loss $13.5M; Sells JZP898 Asset, Repays Debt
AI Summary
Werewolf Therapeutics reported a net loss of $13.5 million for Q1 2026, an improvement from $18.1 million in Q1 2025. The company announced it entered an asset purchase agreement with Jazz Pharmaceuticals for the JZP898 IFNα program, previously licensed to Jazz. Additionally, Werewolf repaid all obligations under its loan and security agreement with K2 HealthVentures and continues to explore strategic options to maximize shareholder value.
Key Highlights
- Entered asset purchase agreement with Jazz Pharmaceuticals for JZP898 IFNα program.
- Repaid all obligations under the loan and security agreement with K2 HealthVentures.
- Net loss for Q1 2026 was $13.5 million, down from $18.1 million in Q1 2025.
- Research and development expenses decreased to $8.2 million from $13.1 million year-over-year.
- Cash and cash equivalents were $46.5 million as of March 31, 2026.
- General and administrative expenses were $5.1 million, up from $4.9 million year-over-year.